Via the mechanism of the autologous tumor cell vaccine, immunization with engineered tumor cells leads to the production of IL-2, a crucial cytokine that promotes Th1 immunity, as well as the development of a strong tumor suppression impact via high IFN-γ production and elevated NK cells and cyto-toxic cells. This evidence concerns the gene IFNG and neoplasm.